Investigation of melatonin effect on the outcome of moderate and severe diffuse axonal injury (DAI) - A randomized, placebo-controlled clinical trial DOI Creative Commons

Alireza Ghaedamini,

Saeed Karamoozian,

Mohammad Khaksari

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 18, 2024

Abstract Objective The efficacy of melatonin in improving diffuse axonal injury has not been evaluated. This study investigated the effect on moderate and severe outcomes. Methods was a randomized clinical trial. case group (N = 35) received 3mg oral melatonin, control Placebo. extended-Glasgow Outcome Scale (e-GOS) Functional Independence Measure (FIM) scores at baseline, 1 month, 3 months, 6 months after were defined as primary outcomes, Glasgow Coma (GCS) 24 hours, 48 week, 2week until discharge secondary Results A total 70 patients enrolled randomly allocated into intervention (n placebo groups. results showed that there no statistically significant difference between GOS (P > 0.05) FIM hospitalization but mean E-GOS 0.001) first month significantly higher group. Conclusions use low-cost safe medicine complementary treatment people with DAI can accelerates functional recovery.

Language: Английский

Melatonin enhances neurogenesis and neuroplasticity in long-term recovery following cerebral ischemia in mice DOI
Merve Beker, Mustafa Çağlar Beker, Birsen Elibol

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: 1871(4), P. 167738 - 167738

Published: Feb. 22, 2025

Language: Английский

Citations

1
Endoplasmic reticulum stress in the pathogenesis of chemotherapy‐induced mucositis: Physiological mechanisms and therapeutic implications DOI Creative Commons
Femke Heindryckx, Markus Sjöblom

Acta Physiologica, Journal Year: 2024, Volume and Issue: 240(8)

Published: June 14, 2024

Chemotherapy is a common and effective treatment for cancer, but these drugs are also associated with significant side effects affecting patients' well-being. One such debilitating effect mucositis, characterized by inflammation, ulcerations, altered physiological functions of the gastrointestinal (GI) tract's mucosal lining. Understanding mechanisms chemotherapy-induced intestinal mucositis (CIM) crucial developing preventive measures supportive care. Chemotherapeutics not only target cancer cells rapidly dividing in GI tract. These disrupt endoplasmic reticulum (ER) homeostasis, leading to ER-stress activation unfolded protein response (UPR) various epithelial cell types. The UPR triggers signaling pathways that exacerbate tissue inflammation damage, influence differentiation fate cells, compromise integrity barrier. factors contribute significantly development progression. In this review, we aim give an in-depth overview role its impact on function. This will provide valuable insights into underlying highlighting potential therapeutic interventions could improve treatment-outcomes quality life patients.

Language: Английский

Citations

6
The effects of melatonin supplementation on neurobehavioral outcomes and clinical severity in rodent models of multiple sclerosis; a systematic review and meta-analysis DOI
Hadis Razmaray, Ehsan Nasiri, Pouya Vakilipour

et al.

Inflammopharmacology, Journal Year: 2024, Volume and Issue: 32(2), P. 927 - 944

Published: Jan. 22, 2024

Language: Английский

Citations

4
Investigation of melatonin effect on the outcome of moderate and severe diffuse axonal injury (DAI) - A randomized, placebo-controlled clinical trial DOI Creative Commons

Alireza Ghaedamini,

Saeed Karamoozian,

Mohammad Khaksari

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 18, 2024

Abstract Objective The efficacy of melatonin in improving diffuse axonal injury has not been evaluated. This study investigated the effect on moderate and severe outcomes. Methods was a randomized clinical trial. case group (N = 35) received 3mg oral melatonin, control Placebo. extended-Glasgow Outcome Scale (e-GOS) Functional Independence Measure (FIM) scores at baseline, 1 month, 3 months, 6 months after were defined as primary outcomes, Glasgow Coma (GCS) 24 hours, 48 week, 2week until discharge secondary Results A total 70 patients enrolled randomly allocated into intervention (n placebo groups. results showed that there no statistically significant difference between GOS (P > 0.05) FIM hospitalization but mean E-GOS 0.001) first month significantly higher group. Conclusions use low-cost safe medicine complementary treatment people with DAI can accelerates functional recovery.

Language: Английский

Citations

0